282 related articles for article (PubMed ID: 31245927)
1. Silencing CDR1as enhances the sensitivity of breast cancer cells to drug resistance by acting as a miR-7 sponge to down-regulate REGγ.
Yang W; Yang X; Wang X; Gu J; Zhou D; Wang Y; Yin B; Guo J; Zhou M
J Cell Mol Med; 2019 Aug; 23(8):4921-4932. PubMed ID: 31245927
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7.
Yang W; Gu J; Wang X; Wang Y; Feng M; Zhou D; Guo J; Zhou M
J Cell Mol Med; 2019 May; 23(5):3166-3177. PubMed ID: 30884120
[TBL] [Abstract][Full Text] [Related]
3. Circular RNA Cdr1as sensitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition.
Yuan W; Zhou R; Wang J; Han J; Yang X; Yu H; Lu H; Zhang X; Li P; Tao J; Wei J; Lu Q; Yang H; Gu M
Mol Oncol; 2019 Jul; 13(7):1559-1576. PubMed ID: 31131537
[TBL] [Abstract][Full Text] [Related]
4. miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGγ.
Shi Y; Luo X; Li P; Tan J; Wang X; Xiang T; Ren G
Cancer Lett; 2015 Mar; 358(1):27-36. PubMed ID: 25511742
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of CircRNA CDR1as specifically triggered low-dose Diosbulbin-B induced gastric cancer cell death by regulating miR-7-5p/REGγ axis.
Li C; Li M; Xue Y
Biomed Pharmacother; 2019 Dec; 120():109462. PubMed ID: 31542615
[TBL] [Abstract][Full Text] [Related]
6. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
7. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
8. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
10. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
11. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of long noncoding RNA CRNDE suppresses drug resistance of liver cancer cells by increasing microRNA-33a expression and decreasing HMGA2 expression.
Han S; Han B; Li Z; Sun D
Cell Cycle; 2019 Oct; 18(19):2524-2537. PubMed ID: 31416393
[TBL] [Abstract][Full Text] [Related]
13. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
Feng LL; Shen FR; Zhou JH; Chen YG
Gene; 2019 May; 696():105-112. PubMed ID: 30738960
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.
Zhang M; Yang L; Hou L; Tang X
Bioengineered; 2021 Dec; 12(2):9239-9250. PubMed ID: 34806925
[TBL] [Abstract][Full Text] [Related]
16. miR-100 Reverses Cisplatin Resistance in Breast Cancer by Suppressing HAX-1.
Wu G; Zhou W; Pan X; Sun Y; Xu H; Shi P; Li J; Gao L; Tian X
Cell Physiol Biochem; 2018; 47(5):2077-2087. PubMed ID: 29975932
[TBL] [Abstract][Full Text] [Related]
17. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
18. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer.
He H; Tian W; Chen H; Jiang K
Tumour Biol; 2016 Feb; 37(2):1599-607. PubMed ID: 26298722
[TBL] [Abstract][Full Text] [Related]
19. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell.
Wang X; Tu S; Tan J; Tian T; Ran L; Rodier JF; Ren G
Med Oncol; 2011 Mar; 28(1):31-41. PubMed ID: 20467919
[TBL] [Abstract][Full Text] [Related]
20. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
